Liquan Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liquan Zhou has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Yimiao Zhou
Hunan Engineering and Technology Research Center for Health Products and Life Science, School of Pharmacy Hunan University of Chinese Medicine Changsha China
5 shared publications - Zuowei Xiao
Hunan Engineering and Technology Research Center for Health Products and Life Science, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China
5 shared publications - Chen Ding
Homologous Innovation Laboratory of Medicine and Food, Hunan University of Chinese Medicine, Changsha 410208, China
3 shared publications - Lin Yang
Guizhou Institute of Crop Germplasm Resources, Guizhou Academy of Agricultural Sciences, Guiyang 550006, China
2 shared publications - Jiani Li
Hunan Engineering and Technology Research Center for Health Products and Life Science, Hunan University of Chinese Medicine, Changsha 410208, China
1 shared publication - Lin Yang
Hunan Engineering and Technology Research Center for Health Products and Life Science, School of Pharmacy Hunan University of Chinese Medicine Changsha China
1 shared publication
Latest Publications
- Open Access
Advances in Nano-Drug Delivery Systems for Chronic Autoimmune Diseases: A Focus on Diabetes Mellitus, Inflammatory Bowel Disease, and Rheumatoid Arthritis
The global prevalence of autoimmune diseases ranges from 3% to 8%, with women at a significantly higher risk than men. The core mechanisms underlying these diseases include impaired T-cell and B-cell immune tolerance, abnormal cytokine production, and aberrant activation of related signaling pathways. Conventional treatments primarily focus on suppressing immune responses, but their efficacy remains limited and they are often associated with substantial side effects. Nanomedicine leverages nanoscale materials to enable precise diagnosis and targeted therapy. Nanocarriers can penetrate biological barriers, enhance cellular uptake, and prolong circulation time in vivo, demonstrating considerable potential for drug delivery. Common nanoscale drug delivery platforms include nanoparticles, polymeric micelles, liposomes, dendrimers, mesoporous materials, hydrogels, and exosomes. Each carrier type possesses distinct characteristics in terms of drug-loading capacity, stability, responsiveness, and biocompatibility, thereby enabling targeted delivery and controlled release. This review summarizes recent advances in nano-delivery technologies for three representative chronic autoimmune diseases: diabetes mellitus (DM), inflammatory bowel disease (IBD), and rheumatoid arthritis (RA). Nano-delivery systems can improve therapeutic outcomes by optimizing drug delivery, targeting complications, and modulating the pathological microenvironment. They enhance drug bioavailability, reduce off-target and systemic adverse effects, and provide novel strategies for the precise and efficient treatment of chronic autoimmune diseases.
Open AccessAdvances in Nano-Drug Delivery Systems for Chronic Autoimmune Diseases: A Focus on Diabetes Mellitus, Inflammatory Bowel Disease, and Rheumatoid Arthritis
The global prevalence of autoimmune diseases ranges from 3% to 8%, with women at a significantly higher risk than men. The core mechanisms underlying these diseases include impaired T-cell and B-cell immune tolerance, abnormal cytokine production, and aberrant activation of related signaling pathways. Conventional treatments primarily focus on suppressing immune responses, but their efficacy remains limited and they are often associated with substantial side effects. Nanomedicine leverages nanoscale materials to enable precise diagnosis and targeted therapy. Nanocarriers can penetrate biological barriers, enhance cellular uptake, and prolong circulation time in vivo, demonstrating considerable potential for drug delivery. Common nanoscale drug delivery platforms include nanoparticles, polymeric micelles, liposomes, dendrimers, mesoporous materials, hydrogels, and exosomes. Each carrier type possesses distinct characteristics in terms of drug-loading capacity, stability, responsiveness, and biocompatibility, thereby enabling targeted delivery and controlled release. This review summarizes recent advances in nano-delivery technologies for three representative chronic autoimmune diseases: diabetes mellitus (DM), inflammatory bowel disease (IBD), and rheumatoid arthritis (RA). Nano-delivery systems can improve therapeutic outcomes by optimizing drug delivery, targeting complications, and modulating the pathological microenvironment. They enhance drug bioavailability, reduce off-target and systemic adverse effects, and provide novel strategies for the precise and efficient treatment of chronic autoimmune diseases.
- Open Access
- 10 June 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (6) , e71999
Structural Characterization and Hypoglycemic Effects of a Purified Polysaccharide From Cinnamomum cassia
A purified polysaccharide, designated CCP1A, was extracted and isolated from Cinnamomum cassia bark using ultrasonic‐assisted composite enzymatic extraction followed by DEAE‐52 and Sephadex G‐100 column chromatography. CCP1A had a molecular weight of 8.161 kDa and was primarily composed of glucose and galacturonic acid, with minor amounts of rhamnose, arabinose, galactose, xylose, and mannose. Spectroscopic analyses (FT‐IR and 1 H NMR) confirmed the coexistence of α‐ and β‐glycosidic linkages and a pyranose ring structure. The Congo red assay indicated a stable helical conformation, and transmission electron microscopy revealed dendritic, coiled aggregates. In a mouse model of type 2 diabetes induced by a high‐fat diet combined with low‐dose streptozotocin, oral administration of CCP1A (100, 200, and 300 mg/kg/day for 4 weeks) dose‐dependently reduced fasting blood glucose, improved glucose tolerance and lipid profiles (TG, TC, LDL‐C, and HDL‐C), and alleviated polydipsia, polyphagia, weight loss, as well as pancreatic pathological damage. Mechanistically, CCP1A suppressed intestinal α‐amylase and α‐glucosidase activities, promoted hepatic and muscle glycogen synthesis, upregulated the hepatic mRNA expression of GCK, GLUT2, PI3K, AKT, and Nrf2, downregulated PEPCK mRNA expression, increased serum levels of T‐SOD, GSH‐Px, CAT, and T‐AOC, and decreased MDA and GSP levels. These findings suggest that CCP1A exerts multi‐target hypoglycemic effects potentially involving inhibition of intestinal glucose absorption, modulation of insulin signaling‐related genes, promotion of glycogen synthesis, suppression of gluconeogenesis, and upregulation of Nrf2 mRNA. Hence, CCP1A represents a promising natural candidate for functional food development against type 2 diabetes.
- 10 June 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (6) , e71999
Open AccessStructural Characterization and Hypoglycemic Effects of a Purified Polysaccharide From Cinnamomum cassia
A purified polysaccharide, designated CCP1A, was extracted and isolated from Cinnamomum cassia bark using ultrasonic‐assisted composite enzymatic extraction followed by DEAE‐52 and Sephadex G‐100 column chromatography. CCP1A had a molecular weight of 8.161 kDa and was primarily composed of glucose and galacturonic acid, with minor amounts of rhamnose, arabinose, galactose, xylose, and mannose. Spectroscopic analyses (FT‐IR and 1 H NMR) confirmed the coexistence of α‐ and β‐glycosidic linkages and a pyranose ring structure. The Congo red assay indicated a stable helical conformation, and transmission electron microscopy revealed dendritic, coiled aggregates. In a mouse model of type 2 diabetes induced by a high‐fat diet combined with low‐dose streptozotocin, oral administration of CCP1A (100, 200, and 300 mg/kg/day for 4 weeks) dose‐dependently reduced fasting blood glucose, improved glucose tolerance and lipid profiles (TG, TC, LDL‐C, and HDL‐C), and alleviated polydipsia, polyphagia, weight loss, as well as pancreatic pathological damage. Mechanistically, CCP1A suppressed intestinal α‐amylase and α‐glucosidase activities, promoted hepatic and muscle glycogen synthesis, upregulated the hepatic mRNA expression of GCK, GLUT2, PI3K, AKT, and Nrf2, downregulated PEPCK mRNA expression, increased serum levels of T‐SOD, GSH‐Px, CAT, and T‐AOC, and decreased MDA and GSP levels. These findings suggest that CCP1A exerts multi‐target hypoglycemic effects potentially involving inhibition of intestinal glucose absorption, modulation of insulin signaling‐related genes, promotion of glycogen synthesis, suppression of gluconeogenesis, and upregulation of Nrf2 mRNA. Hence, CCP1A represents a promising natural candidate for functional food development against type 2 diabetes.
- Open Access
Chemical Compositions, Traditional Applications, and Biological Activities of Gnaphalium affine D. Don: A Comprehensive Review
Gnaphalium affine D. Don (G. affine), a genus within the genus Gnaphalium of the Asteraceae family, is recognized as a significant medicinal resource. Phytochemical investigations identified various bioactive compounds in G. affine, including flavonoids, terpenoids, phenolic acids, alkaloids, and amino acids. These compounds exhibit a range of pharmacological activities such as antimicrobial, cough expectorant, antioxidant, and anti-inflammatory properties, as well as the regulation of lipid and glucose metabolism, reduction of uric acid levels, hepatoprotective effects, and anti-tumor activities. However, research concerning the chemical composition, biological activities, and potential applications of synthesized G. affine remains limited. In light of the growing interest in this species, the present paper aims to provide a comprehensive overview of the current research advancements related to the traditional applications, chemical constituents, and biological effects of G. affine. Additionally, this study will discuss future prospects for the development and application of G. affine to enhance its utilization in various fields.
Open AccessChemical Compositions, Traditional Applications, and Biological Activities of Gnaphalium affine D. Don: A Comprehensive Review
Gnaphalium affine D. Don (G. affine), a genus within the genus Gnaphalium of the Asteraceae family, is recognized as a significant medicinal resource. Phytochemical investigations identified various bioactive compounds in G. affine, including flavonoids, terpenoids, phenolic acids, alkaloids, and amino acids. These compounds exhibit a range of pharmacological activities such as antimicrobial, cough expectorant, antioxidant, and anti-inflammatory properties, as well as the regulation of lipid and glucose metabolism, reduction of uric acid levels, hepatoprotective effects, and anti-tumor activities. However, research concerning the chemical composition, biological activities, and potential applications of synthesized G. affine remains limited. In light of the growing interest in this species, the present paper aims to provide a comprehensive overview of the current research advancements related to the traditional applications, chemical constituents, and biological effects of G. affine. Additionally, this study will discuss future prospects for the development and application of G. affine to enhance its utilization in various fields.
- Open Access
- 29 August 2025
- Published by Wiley in Food Science & Nutrition
- Vol. 13 (9) , e70814
Cinnamon Essential Oil Delivery Systems: Preparation Processes, Packaging Forms, and Industrialization Potentials
Cinnamon essential oil (CEO), recognized for its broad‐spectrum antimicrobial and antioxidant properties, is a natural alternative to synthetic preservatives. However, its high volatility, low water solubility, and strong odor limit direct application. This review examines advanced delivery systems—including emulsions, nanocarriers, molecular inclusion complexes, microcapsules, and liposomes—designed to enhance CEO stability, mask undesirable flavors, and enable controlled release. These systems are integrated into active, edible, and intelligent packaging forms. Active packaging extends food shelf life by inhibiting microbial growth, while intelligent packaging incorporates anthocyanin indicators for real‐time freshness monitoring via pH‐responsive color changes. Despite promising laboratory results, industrialization faces challenges such as high equipment costs, expensive raw materials, and stability issues. Future advancements require process optimization, low‐cost carrier development, and composite material strategies to promote functional, intelligent, and scalable CEO delivery systems.
- 29 August 2025
- Published by Wiley in Food Science & Nutrition
- Vol. 13 (9) , e70814
Open AccessCinnamon Essential Oil Delivery Systems: Preparation Processes, Packaging Forms, and Industrialization Potentials
Cinnamon essential oil (CEO), recognized for its broad‐spectrum antimicrobial and antioxidant properties, is a natural alternative to synthetic preservatives. However, its high volatility, low water solubility, and strong odor limit direct application. This review examines advanced delivery systems—including emulsions, nanocarriers, molecular inclusion complexes, microcapsules, and liposomes—designed to enhance CEO stability, mask undesirable flavors, and enable controlled release. These systems are integrated into active, edible, and intelligent packaging forms. Active packaging extends food shelf life by inhibiting microbial growth, while intelligent packaging incorporates anthocyanin indicators for real‐time freshness monitoring via pH‐responsive color changes. Despite promising laboratory results, industrialization faces challenges such as high equipment costs, expensive raw materials, and stability issues. Future advancements require process optimization, low‐cost carrier development, and composite material strategies to promote functional, intelligent, and scalable CEO delivery systems.
- Open Access
Mechanistic Advances in Hypoglycemic Effects of Natural Polysaccharides: Multi-Target Regulation of Glycometabolism and Gut Microbiota Crosstalk
Natural polysaccharides (NPs), as a class of bioactive macromolecules with multitarget synergistic regulatory potential, exhibit significant advantages in diabetes intervention. This review systematically summarizes the core hypoglycemic mechanisms of NPs, covering structure–activity relationships, integration of the gut microbiota–metabolism–immunity axis, and regulation of key signaling pathways. Studies demonstrate that the molecular weight, branch complexity, and chemical modifications of NPs mediate their hypoglycemic activity by influencing bioavailability and target specificity. NPs improve glucose metabolism through multiple pathways: activating insulin signaling, improving insulin resistance (IR), enhancing glycogen synthesis, inhibiting gluconeogenesis, and regulating gut microbiota homeostasis. Additionally, NPs protect pancreatic β-cell function via the nuclear factor E2-related factor 2 (Nrf2)/Antioxidant Response Element (ARE) antioxidant pathway and Toll-like receptor 4 (TLR4)/nuclear factor-κB (NF-κB) anti-inflammatory pathway. Clinical application of NPs still requires overcoming challenges such as resolving complex structure–activity relationships and dynamically integrating cross-organ signaling. Future research should focus on integrating multi-omics technologies (e.g., metagenomics, metabolomics) and organoid models to decipher the cross-organ synergistic action networks of NPs, and promote their translation from basic research to clinical applications.
Open AccessMechanistic Advances in Hypoglycemic Effects of Natural Polysaccharides: Multi-Target Regulation of Glycometabolism and Gut Microbiota Crosstalk
Natural polysaccharides (NPs), as a class of bioactive macromolecules with multitarget synergistic regulatory potential, exhibit significant advantages in diabetes intervention. This review systematically summarizes the core hypoglycemic mechanisms of NPs, covering structure–activity relationships, integration of the gut microbiota–metabolism–immunity axis, and regulation of key signaling pathways. Studies demonstrate that the molecular weight, branch complexity, and chemical modifications of NPs mediate their hypoglycemic activity by influencing bioavailability and target specificity. NPs improve glucose metabolism through multiple pathways: activating insulin signaling, improving insulin resistance (IR), enhancing glycogen synthesis, inhibiting gluconeogenesis, and regulating gut microbiota homeostasis. Additionally, NPs protect pancreatic β-cell function via the nuclear factor E2-related factor 2 (Nrf2)/Antioxidant Response Element (ARE) antioxidant pathway and Toll-like receptor 4 (TLR4)/nuclear factor-κB (NF-κB) anti-inflammatory pathway. Clinical application of NPs still requires overcoming challenges such as resolving complex structure–activity relationships and dynamically integrating cross-organ signaling. Future research should focus on integrating multi-omics technologies (e.g., metagenomics, metabolomics) and organoid models to decipher the cross-organ synergistic action networks of NPs, and promote their translation from basic research to clinical applications.